In this issue:
5α-reductase inhibitors and prostate cancer mortality
Nivolumab + rucaparib for mCRPC
Factors associated with risk of prostate cancer diagnosis
Enzalutamide or abiraterone acetate + prednisone for mCRPC
Androgen receptor splice variant-7 as a biomarker of clinical response
PSMA-PET-guided salvage radiation therapy outcomes
Urine and prostate microbiome linked to prostate cancer risk
68Ga-PSMA PET/CT in primary staging of prostate cancer
Impact of family history on detection of high-grade prostate cancer
Family history of cancer and outcomes of AS
Please login below to download this issue (PDF)